DPX® Delivery Technology

BioVaxys is developing a unique non-aqueous, lipid-based delivery technology called DPX™, which is proven to incorporate an array of bioactive molecules into a single formulation to create long-lasting, targeted immune responses that mitigate disease without severe toxicity.

The versatility of the DPX technology is remarkable. It allows us to package and deliver a wide array of bioactive cargo including peptides, whole proteins, mRNA, DNA, small molecules, and virus-like particles.

DPX has the capability of driving targeted and durableimmune responses. The non-aqueous DPX formulation prevents cargo from leachinginto tissue, mimicking the natural flow of antigens through the immune systemto orchestrate a robust anti-cancer immune attack. This unique feature alsoinsulates cargo from non-specific interactions, ensuring that DPX is welltolerated and can be administered across many doses to ensure persistent immuneeducation.

Physiologic Immune Activation

The DPX delivery platform incites engulfment of its cargo byAntigen Presenting Cells, which in turn activates a specific immune response mediated by T and B cells in the lymph node. The introduction of cargo to the immune system in this manner, mimics the natural exposure of antigens to the immune system.

Physiologic Immune Activation

The DPX delivery platform incites engulfment of its cargo byAntigen Presenting Cells, which in turn activates a specific immune response mediated by T and B cells in the lymph node. The introduction of cargo to the immune system in this manner, mimics the natural exposure of antigens to the immune system.

DPX® Delivery Technology

The versatility of the DPX technology is remarkable. It allows us to package and deliver a wide array of bioactive cargo including peptides, whole proteins, mRNA, DNA, small molecules, and virus-like particles.

Physiologic Immune Activation

How DPX Works

Physiologic Immune Activation